Journals / Türk Oftalmoloji Dergisi / 2019 / Cilt: 49 - Sayı: 1

Central Serous Chorioretinopathy: A Complication Associated with Behçet’s Disease Treatment

Santral Seröz Koryoretinopati: Behçet Hastalığı Tedavisine Eşlik Eden Bir Komplikasyon

Pages
40–43
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this study we present two patients, one man and one woman, who developed acute CSCR while under systemic steroid treatment for Behçet’s disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Central serous chorioretinopathy (CSCR) is characterized by a well-defined serous choroidal detachment of the retinal pigment epithelium with one or more focal lesions of the neurosensory retina.
📊
Key Findings & Data:Risk factors for CSCR are psychosocial stress, increased endogenous catecholamine, and increased endogenous cortisol.
💡
Conclusion & Impact:In this study we present two patients, one man and one woman, who developed acute CSCR while under systemic steroid treatment for Behçet’s disease.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Central serous chorioretinopathy (CSCR) is characterized by a well-defined serous choroidal detachment of the retinal pigment epithelium with one or more focal lesions of the neurosensory retina. Risk factors for CSCR are psychosocial stress, increased endogenous catecholamine, and increased endogenous cortisol. Systemic steroids can cause ocular side effects such as cataract development, increased intraocular pressure, and less frequently the development of CSCR, which can resolve spontaneously with close follow-up and simple treatment modification. CSCR should be considered in patients who complain of worsening vision under steroid treatment for pathologies requiring steroid therapy. In this study we present two patients, one man and one woman, who developed acute CSCR while under systemic steroid treatment for Behçet’s disease.

Özet

Santral seröz koryoretinopati (SSKR) retina pigment epitelinin bir veya daha fazla fokal lezyon birlikteliğinde nörosensöriyel retinanın iyisınırlı seröz dekolmanı ile karakterizedir. Psikososyal stresler, endojen katekolamin artışı ve endojen kortizol artışı risk faktörlerindendir.Sistemik steroidler katarakt gelişimi, intraoküler basınç artışı ve daha az sıklıkla, yakın hasta takibi ve basit bir tedavi değişikliği ilespontan düzelebilen SSKR gelişimi gibi oküler yan etkilere neden olabilir. Steroid tedavisi gerektiren patolojilerde steroid tedavisialtında görmesinin kötüleştiğinden şikayet eden hastalarda SSKR akla getirilmelidir. Bu çalışmada Behçet hastalığı nedeniyle sistemiksteroid tedavisi alırken akut SSKR gelişen 1 kadın ve 1 erkek olmak üzere 2 olgu sunulmuştur.

🔖

Cite This Article

ORDUYILMAZ, B., SAATÇİ, A. O., DOĞANAY, N., YILMAZ, M. B., AYDIN, E. (2022). Central Serous Chorioretinopathy: A Complication Associated with Behçet’s Disease Treatment. Türk Oftalmoloji Dergisi, Cilt: 49 - Sayı: 1, 40–43. https://ajindex.com/articles/637756

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Okada AA. Drug therapy in Behçet’s disease. Ocul Immunol Inflamm. 2000;8:85-91
  2. Grixti A, Kumar V. Steroid induced central serous chorioretinopathy in giant cell arteritis. Case Rep Ophthalmol Med. 2013;2013:924037
  3. Fardin B, Weissgold DJ. Central serous chorioretinopathy after inhaled steroid use for post-mycoplasmal bronchospasm. Br J Ophthalmol. 2002;86:1065-1066
  4. Balakrishnan S, Apsingi S, Manjure SB. Sudden loss of visual acuity following intra-articular steroid injection in to the knee joint: a case report. Cases J. 2008;1:428
  5. Gäckle HC, Lang GE, Freissler KA, Lang GK. [Central serous chorioretinopathy. Clinical, fluorescein angiography and demographic aspects]. Ophthalmologe. 1998;95:529-533
  6. Tsai DC, Chen SJ, Huang CC, Chou P, Chung CM, Huang PH, Lin SJ, Chen JW, Chen TJ, Leu HB, Chan WL. Epidemiology of idiopathic central serous chorioretinopathy in Taiwan, 2001-2006: a population-based study. PLoS One. 2013;8:e66858
  7. Carvalho-Recchia CA, Yannuzzi LA, Negrão S, Spaide RF, Freund KB, Rodriguez-Coleman H, Lenharo M, Iida T. Corticosteroids and central serous chorioretinopathy. Ophthalmology. 2002;109:1834-1837
  8. Stoffelns BM, Kramann C, Schoepfer K. [Central serouschorioretinopathy (CSC) and corticosteroids]. Klin Monbl Augenheilkd. 2008;225:370-375
  9. Cassel GH, Brown GC, Annesley WH. Central serous chorioretinopathy: a seasonal variation? Br J Ophthalmol. 1984;68:724-726
  10. Siaudvytyte L, Diliene V, Miniauskiene G, Balciuniene VJ. Photodynamic therapy and central serous chorioretinopathy. Med Hypothesis Discov Innov Ophthalmol. 2012;1:67-71
  11. Zamir E. Central serous retinopathy associated with adrenocorticotrophic hormone therapy. A case report and a hypothesis. Graefes Arch Clin Exp Ophthalmol. 1997;235:339-344
  12. Elbay A, Yenigün A, Özdemir H, Çalım ÖF, Ekinci C, Çetinkaya R. Kortikosteroid içerikli burun spreyi kullanımının santral seröz koryoretinopati gelişiminde rolü var mıdır? Anatol Clin. 2017;22:163-168
  13. Aydın B, Özdek Ş, Konuk O, Gürelık G, Akata F, Hasanreisoğlu B. Retrobulber Nörit Tedavisi İçin Sistemik Steroid Kullanan Hastada Gelişen İki Taraflı Santral Seröz Koryoretinopati. Ret-Vit. 2009;17:210-212
  14. Cebeci Z, Oray M, Bayraktar Ş, Tuğal-Tutkun İ, Kır N. Atypical Central Serous Chorioretinopathy. Turk J Ophthalmol. 2017;47:238-242
  15. Ponce CM, Mohidat HM, Garcia CA. Central serous chorioretinopathy after blunt trauma. BMJ Case Rep. 2012:2012
  16. Breukink MB, Mohabati D, van Dijk EH, den Hol